An analysis by UsAgainstAlzheimer’s of the 92 medicines in development found that of those in Phases 2 and 3, approximately 75 percent have the potential to be disease-modifying treatments.
Top Biopharmaceutical Research Companies Publish Update On The State Of Alzheimer’s Research In US
